Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04116476 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
A Phase 1 study, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT04116476 is a Phase 1 study that has completed, run by Tanabe Pharma America. The registered enrollment target is 23 participants.
The verdict
NCT04116476, a Phase 1 study, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects with Normal and Impaired Hepatic Function
Interventions
- DRUG MT-7117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2021-02-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04116476
The ClinicalTrials.gov registry entry for NCT04116476 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MT-7117 is the first listed.
NCT04116476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04116476 about?
NCT04116476 is a clinical study titled "Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function". An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects with Normal and Impaired Hepatic Function
What is the current status of trial NCT04116476?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2019-08-01. Estimated completion is 2021-02-16.
What interventions are being tested in trial NCT04116476?
The interventions under investigation include: MT-7117 (DRUG).
Who is sponsoring clinical trial NCT04116476?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.